Conditions

This post was originally published on this site Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells against blood and solid cancers. Under the terms of the agreement, the companies will test Editas’ CRISPR technology as a means to engineer Gamida’s…

This post was originally published on this site Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a study of two clinical trials suggests. The study, “Once-Weekly Versus Twice-Weekly Carfilzomib In Patients With Newly Diagnosed Multiple Myeloma: A Pooled Analysis Of…

This post was originally published on this site Olympic gymnast and ovarian cancer survivor Shannon Miller will be the keynote speaker March 15 for the second annual Ovarian Cancer Heroes event. Three individuals will be honored at the event, being held at the Hawaii Convention Center in Honolulu during the Society of Gynecologic Oncology (SGO) Annual…

This post was originally published on this site Using diagnostic images, artificial intelligence is better able to predict ovarian cancer survival than other current prognostic methods, a study suggests. The study, “A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer,” was published in Nature Communications. A diagnosis of ovarian cancer…

This post was originally published on this site A new investigator-sponsored clinical trial is recruiting women with recurrent, platinum-sensitive ovarian cancer to study a combination of Hemispherx Biopharma’s investigational product Ampligen (rintatolimod) plus chemo-immunotherapy, the company announced. The Phase 1/2 trial (NCT03734692) is being conducted at the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, under the supervision of…

This post was originally published on this site A Phase 2 trial exploring Aivita Biomedical’s cell therapy AVOVA-1 for ovarian cancer has treated its first patient and continues to recruit participants across eight sites in the United States. So far, 11 patients have been included in the study, including one who received the planned eight treatment sessions, under…

This post was originally published on this site Five Prime Therapeutics’ ongoing Phase 1 clinical trial has advanced to its Phase 1b expansion portion, in which researchers have begun giving breast, ovarian, and endometrial cancer patients an optimal dose of the company’s immune checkpoint inhibitor, FPA150. “We are very pleased with the progress of our FPA150 clinical…

This post was originally published on this site A blood test measuring the levels of PSA — a well-known marker of prostate cancer — cuts deaths from the disease by nearly 30%, the longest screening study on prostate cancer shows. The study, “Improving Prostate Cancer Screening: 22-Year Follow-up in a Randomized Trial,” followed 20,000 men…

This post was originally published on this site The 12th annual New York GU: Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies will focus on essential clinical topics in disease management. The meeting, hosted by Physicians’ Education Resource, a top resource for continuing medical education, will be March 15-16 in New York. It will be…

This post was originally published on this site Leap Therapeutics is launching a Phase 1/2 trial to study its lead candidate DKN-01, alone or in combination with chemotherapy, for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients whose tumors have elevated Dickkopf-1 (DKK1) levels. The trial (NCT03837353), led by David Wise, MD, PhD, will be conducted…

This post was originally published on this site African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans diagnosed with prostate cancer have had worse survival outcomes than whites. The reasons for this are complex and…

This post was originally published on this site A combination of Bristol-Myers Squibb’s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor burden in castration-resistant prostate cancer patients whose tumors have spread, interim Phase 2 results show. Findings from the CheckMate 650 trial (NCT02985957) were recently shared at the 2019 Genitourinary Cancers Symposium in San Francisco in a presentation…